EHS
EHS

Merck eyes Seagen to beef up its cancer drug portfolio



Good morning, everyone, and welcome to another working week, although today is actually a holiday on this side of the pond. So consider this something of a bonus feature. If nothing else, this is an opportunity to take a moment to quickly catch up on events over a cup or two of stimulation before pursuing other matters. And for those of you entrenched in the usual routine, well, time to get cracking. Whatever your pursuit, we hope your day goes well and look forward to engaging during the rest of the week…

Merck is eyeing a purchase of Seagen in order to beef up its portfolio of cancer drugs, according to The Wall Street Journal. Talks have been under way for a while and a deal is not imminent, because pulling one off could be tricky given the heightened risk of a regulatory challenge. It is possible the companies could end up striking a marketing agreement instead. Seagen helped pioneer a class of cancer therapy that works like a guided missile attacking tumors with toxins. By acquiring Seagen, Merck would bolster its lineup of cancer drugs, led by the blockbuster immunotherapy Keytruda, its top-selling product with $17.2 billion in sales last year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED





Source link

EHS
Back to top button